Advanced technology imaging solution recognized for disruptive improvements in clinical trial data
PHILADELPHIA – October 2, 2018 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced its advanced technology imaging solution has been named a finalist in the 2018 Scrip Awards, Best Technological Development in Clinical Trials – Tech Sponsor-focused category.
Mike Ward, Global Director of Content, Scrip noted, “The 2018 Scrip Awards provide the biopharma industry with an opportunity to acknowledge its highest achievers across the entire value chain, and to recognize the organizations that are using the most sophisticated platforms to catalyze and optimize clinical trial data. We’re pleased to recognize and shortlist ERT for its advancements in improving imaging data quality to support safety and efficacy endpoints during clinical trials.”
ERT’s advanced technology imaging solution is purpose-built for clinical trials, enabling sponsors to improve imaging data consistency, objectivity and transparency and to run more efficient studies. The solution enables the analysis, management, reporting and submission of high-quality imaging data that supports clinical trial objectives and meets regulators’ increasing requests for imaging endpoints in clinical development.
“We’re pleased to be among this distinguished group of finalists being recognized for their dedication to advancing drug development,” said Tim Kulbago, Vice President of Imaging, ERT. “The current state of imaging in clinical research is dated and ripe for innovative disruption; the industry is in acute need of a comprehensive solution that provides the best technology and science to achieve higher quality data. We’re honored that ERT’s advanced technology imaging solution is being recognized for meeting these needs.”
For more information on ERT’s imaging solution for clinical research, visit ert.com/imaging.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.